CSPC Innovation Pharmaceutical Co., Ltd.
新诺威
300765
Shenzhen Stock Exchange
Company Profile
1. Strong Pipeline of Drug Candidates The Company is committed to developing ADC drugs with favorable clinical therapeutic value. Its ADC pipeline focuses on therapeutic areas with high incidence or significant unmet medical needs, including lung cancer, breast cancer, gastric cancer, colorectal cancer and esophageal squamous cell carcinoma, with targets covering EGFR, Nectin-4, HER2, B7H3, HER3, FRα, ROR1 and DLL3. The Company has formed a rich product portfolio of antibody drugs and ADC drugs, laying a solid foundation for the development of combination therapeutic strategies of ADC drugs with immune checkpoint inhibitors. 2. Advanced Technology Platforms The Company has established two advanced technology platforms to support the development of antibody drugs, ADCs and mRNA vaccines. (1) Antibody Engineering and ADC Platform The Company has built a customized closed-loop system for specific antibody discovery, which adopts both phage display and yeast display technologies to effectively shorten the antibody discovery cycle and improve antibody expression levels. Lead antibody candidates are optimized through the computational engineering platform to enhance key quality attributes such as antibody binding affinity, efficacy and safety. Meanwhile, the Company owns proprietary conjugation technology using engineered microbial transglutaminase, which enables site-specific modification of specific glutamine residues in proteins. This technology can act directly on native antibodies with minimal impact on their original properties, thus achieving excellent selectivity and reactivity to target sites, providing core technical support for the development of next-generation ADC drugs. (2) mRNA Vaccine Development Platform The Company has core technological advantages in the field of mRNA vaccines, with profound technical experience and expertise in optimizing mRNA translation efficiency, stability and immunogenicity. It has built a modular mRNA technology platform covering five core segments: mRNA sequence design, plasmid synthesis, mRNA synthesis and purification, LNP formulation preparation, and quality control and analysis. In mRNA design, free energy minimization algorithms are used to optimize structural stability and translation efficiency, enabling precise regulation of local spatial folding of key regions and breaking through the limitations of traditional methods that only focus on codon composition. Favorable local structures are formed to promote efficient initiation and elongation of ribosomes. At the same time, pre-trained models are adopted for high-throughput screening to accelerate the identification of high-performance structures. In terms of delivery systems, advanced LNP technology is utilized to produce stable and uniform nanoparticles with high encapsulation efficiency, which can effectively improve uptake efficiency by the immune system, providing solid technical support for the R&D and industrialization of mRNA vaccines. 3. Full-Industry-Chain Operational Capabilities The Company has constructed an integrated and independently controllable industrial chain of “R&D–production–commercialization” with efficient collaboration among all segments. On the production side, the Company focuses on building a flexible production system and upgrading processes rather than simply pursuing production capacity scale. Through intelligent scheduling systems and refined whole-process management, it achieves flexible allocation and efficient utilization of production capacity. It also deepens the lean production model, completes the upgrading and renovation of relevant production equipment and environmental protection systems, improving production efficiency and reducing production costs. The supply chain system is stable and controllable, allowing dynamic adjustment of production plans in response to market demand. Combined with the advantages of international authoritative product certifications, the Company further consolidates its market position and provides core support for its production and product advantages. The R&D segment is precisely integrated with production and commercialization, rapidly converting technologies into products and products into market returns, forming a unique industrial chain barrier. 4. Strict Quality Control The Company has strong independent production capabilities and always adheres to the philosophy that “product quality is the life of an enterprise, and pharmaceutical quality outweighs everything”. Quality control and compliance management capabilities are the core foundation for ensuring compliant production, reliable products and brand reputation, as well as an important support for the Company’s sustainable operation. The production process strictly complies with GMP and ISO requirements. The Company is equipped with advanced quality management and testing systems and has established a full-process quality control system, implementing strict supervision over all links from raw material procurement, production and processing to product delivery and market circulation, ensuring stable and reliable product quality. 5. Professional Talent-Driven Development The Company has a professional and stable team with extensive industry experience, solid professional capabilities and diversified technological strengths. It attaches importance to the human resource system, having established sound recruitment and training mechanisms to continuously enhance the team’s professionalism, innovation capability and management capacity, providing human resource support for the Company’s high-quality development. Meanwhile, the Company has built a competitive compensation, incentive and performance appraisal system to fully motivate employees and scientific and technological talents and unlock their innovation potential. It actively introduces top and high-end talents in various technical fields to reserve strength for technological innovation. 6. Resource Integration and Strategic Layout-Driven Development The Company accurately grasps industry development trends and focuses on its core areas of biopharmaceuticals, functional raw materials and health food products. Through scientific strategic layout and diversified resource integration, it addresses business weaknesses, expands development boundaries, improves overall risk resistance and strengthens core competitiveness. In recent years, the Company has integrated high-quality R&D, production and market resources through mergers and acquisitions, strategic cooperation and leveraging parent company resources. It also promotes marketing upgrading and international layout to expand market space, which not only strengthens existing core capabilities but also effectively addresses industry competition challenges, supporting the Company’s long-term high-quality development.
Full description
The Company’s principal businesses cover the research and development, production and commercialization of biopharmaceuticals, functional ingredients and nutritional products. In biopharmaceuticals, the Company focuses on cutting-edge fields including antibody-drug conjugates (ADCs), mRNA vaccines and antibody-based drugs, and has established a professional innovation platform for the biomedical industry. Its functional food and raw material portfolio includes caffeine, vitamin C lozenges and other products. Biopharmaceuticals: CSPC Megalith is engaged in the R&D, production and commercialization of innovative biopharmaceuticals such as monoclonal antibodies, antibody-drug conjugates (ADCs) and mRNA vaccines, with product portfolios covering three major therapeutic areas: oncology, autoimmune diseases and major infectious diseases. It has formed a complete integrated industrial chain of “R&D–production–commercialization”. Nine products of the Company have obtained initial clinical trial approval in China; four products have secured clinical trial approval from the U.S. Food and Drug Administration (FDA); and another two ADC products have advanced to Phase III clinical trials. In January 2025, SYS6010 was granted Breakthrough Therapy Designation. In February 2025, omalizumab for injection (brand name: 恩益坦®) received approval for the indication of moderate to severe persistent allergic asthma, marking the second indication approved for 恩益坦® in China. During the reporting period, driven by innovation, the Company accelerated the advancement of its R&D pipeline. Pertuzumab has completed database lock and achieved anticipated results; DP303c Injection has finished enrollment of subjects in its pivotal clinical trial. A number of other products have progressed to pivotal clinical stages, which are expected to bring new breakthroughs in the treatment of related diseases. The progress of other pipeline programs is being advanced in parallel, establishing a competitive R&D system. A variety of key clinical data have been published, continuously enhancing the Company’s global academic. Functional Ingredients and Nutritional Products: Caffeine is a xanthine alkaloid compound and a central nervous system stimulant. It has effects such as refreshing the mind and awakening consciousness, combating depression, controlling weight, promoting digestion, diuresis, relieving constipation, relieving pain, and enhancing physical agility. It is mainly used as an additive in functional food and beverages as well as a raw material in medicine.In recent years, due to its functions like antioxidation, soothing, and anti-hair loss, the application fields of caffeine have been continuously expanding, and it has also been widely used in cosmetics, daily chemical products and other fields. Relying on stable product quality, cost advantages brought by large-scale production, and a sound supply chain system, CSPC Innovation has successfully become a core partner of top international beverage enterprises and is a global supplier for three major international beverage companies: PepsiCo, The Coca-Cola Company, and Red Bull.